Exact Mass: 425.2721608
Exact Mass Matches: 425.2721608
Found 262 metabolites which its exact mass value is equals to given mass value 425.2721608,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Iervin
C27H39NO3 (425.29297840000004)
D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents > D014704 - Veratrum Alkaloids CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 2330 Jervine (11-Ketocyclopamine) is a potent Hedgehog (Hh) inhibitor with an IC50 of 500-700 nM[1]. Jervine is a natural teratogenic sterodial alkaloid from rhizomes of Veratrum nigrum. Jervine has anti-inflammatory and antioxidant properties[2]. Jervine (11-Ketocyclopamine) is a potent Hedgehog (Hh) inhibitor with an IC50 of 500-700 nM[1]. Jervine is a natural teratogenic sterodial alkaloid from rhizomes of Veratrum nigrum. Jervine has anti-inflammatory and antioxidant properties[2].
Diprenorphine
C26H35NO4 (425.25659500000006)
D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D009292 - Narcotic Antagonists C78272 - Agent Affecting Nervous System > C681 - Opiate Antagonist Same as: D07863
Nafoxidine
D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D004965 - Estrogen Antagonists C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C1821 - Selective Estrogen Receptor Modulator C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor > C1971 - Angiogenesis Activator Inhibitor C274 - Antineoplastic Agent > C129818 - Antineoplastic Hormonal/Endocrine Agent > C481 - Antiestrogen C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C483 - Therapeutic Estrogen C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist D000970 - Antineoplastic Agents C1892 - Chemopreventive Agent
LysoPE(14:0/0:0)
C19H40NO7P (425.2542260000001)
LysoPE(14:0/0:0) is a lysophosphatidylethanolamine or a lysophospholipid. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic however it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Some LPLs serve important signaling functions such as lysophosphatidic acid. Lysophosphatidylethanolamines (LPEs) can function as plant growth regulators with several diverse uses. (LPEs) are approved for outdoor agricultural use to accelerate ripening and improve the quality of fresh produce. They are also approved for indoor use to preserve stored crops and commercial cut flowers. As a breakdown product of phosphatidylethanolamine (PE), LPE is present in cells of all organisms. [HMDB] LysoPE(14:0/0:0) is a lysophosphatidylethanolamine or a lysophospholipid. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic however it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Some LPLs serve important signaling functions such as lysophosphatidic acid. Lysophosphatidylethanolamines (LPEs) can function as plant growth regulators with several diverse uses. (LPEs) are approved for outdoor agricultural use to accelerate ripening and improve the quality of fresh produce. They are also approved for indoor use to preserve stored crops and commercial cut flowers. As a breakdown product of phosphatidylethanolamine (PE), LPE is present in cells of all organisms.
LysoPE(0:0/14:0)
C19H40NO7P (425.2542260000001)
LysoPE(0:0/14:0) is a lysophosphatidylethanolamine or a lysophospholipid. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic however it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Some LPLs serve important signaling functions such as lysophosphatidic acid. Lysophosphatidylethanolamines (LPEs) can function as plant growth regulators with several diverse uses. (LPEs) are approved for outdoor agricultural use to accelerate ripening and improve the quality of fresh produce. They are also approved for indoor use to preserve stored crops and commercial cut flowers. As a breakdown product of phosphatidylethanolamine (PE), LPE is present in cells of all organisms. [HMDB] LysoPE(0:0/14:0) is a lysophosphatidylethanolamine or a lysophospholipid. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic however it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Some LPLs serve important signaling functions such as lysophosphatidic acid. Lysophosphatidylethanolamines (LPEs) can function as plant growth regulators with several diverse uses. (LPEs) are approved for outdoor agricultural use to accelerate ripening and improve the quality of fresh produce. They are also approved for indoor use to preserve stored crops and commercial cut flowers. As a breakdown product of phosphatidylethanolamine (PE), LPE is present in cells of all organisms.
(6Z,8Z)-Hexadeca-6,8-dienedioylcarnitine
(6Z,8Z)-Hexadeca-6,8-dienedioylcarnitine is an acylcarnitine. More specifically, it is an (6Z,8Z)-hexadeca-6,8-dienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (6Z,8Z)-Hexadeca-6,8-dienedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (6Z,8Z)-Hexadeca-6,8-dienedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(4E,6Z)-Hexadeca-4,6-dienedioylcarnitine
(4E,6Z)-Hexadeca-4,6-dienedioylcarnitine is an acylcarnitine. More specifically, it is an (4E,6Z)-hexadeca-4,6-dienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4E,6Z)-Hexadeca-4,6-dienedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (4E,6Z)-Hexadeca-4,6-dienedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(6E,9E)-Hexadeca-6,9-dienedioylcarnitine
(6E,9E)-Hexadeca-6,9-dienedioylcarnitine is an acylcarnitine. More specifically, it is an (6E,9E)-hexadeca-6,9-dienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (6E,9E)-Hexadeca-6,9-dienedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (6E,9E)-Hexadeca-6,9-dienedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(7Z,13Z)-hexadeca-7,13-dienedioylcarnitine
(7Z,13Z)-Hexadeca-7,13-dienedioylcarnitine is an acylcarnitine. More specifically, it is an (7Z,13Z)-hexadeca-7,13-dienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (7Z,13Z)-Hexadeca-7,13-dienedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (7Z,13Z)-Hexadeca-7,13-dienedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(4Z,7Z)-Hexadeca-4,7-dienedioylcarnitine
(4Z,7Z)-Hexadeca-4,7-dienedioylcarnitine is an acylcarnitine. More specifically, it is an (4Z,7Z)-hexadeca-4,7-dienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4Z,7Z)-Hexadeca-4,7-dienedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (4Z,7Z)-Hexadeca-4,7-dienedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(12E,14E)-hexadeca-12,14-dienedioylcarnitine
(12E,14E)-Hexadeca-12,14-dienedioylcarnitine is an acylcarnitine. More specifically, it is an (12E,14Z)-hexadeca-12,14-dienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (12E,14E)-Hexadeca-12,14-dienedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (12E,14E)-Hexadeca-12,14-dienedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
N-Docosahexaenoyl Proline
C27H39NO3 (425.29297840000004)
N-docosahexaenoyl proline belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Docosahexaenoyl amide of Proline. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Docosahexaenoyl Proline is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Docosahexaenoyl Proline is therefore classified as a very long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.
2-Azetidinecarboxylic acid, 3-(3-((aminoiminomethyl)amino)propyl)-1-((4-(((1,1-dimethylethyl)amino)carbonyl)-1-piperazinyl)carbonyl)-4-oxo-, (2S,3R)-
Diprenorphine
C26H35NO4 (425.25659500000006)
Gly-pro-arg-pro
Jervine
C27H39NO3 (425.29297840000004)
Piriprost
C26H35NO4 (425.25659500000006)
Jervine
C27H39NO3 (425.29297840000004)
Jervine is a member of piperidines. Jervine is a natural product found in Veratrum stamineum, Veratrum grandiflorum, and other organisms with data available. Jervine is a steroidal alkaloid with molecular formula C27H39NO3 which is derived from the Veratrum plant genus. Similar to cyclopamine, which also occurs in the Veratrum genus, it is a teratogen implicated in birth defects when consumed by animals during a certain period of their gestation. D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents > D014704 - Veratrum Alkaloids Jervine (11-Ketocyclopamine) is a potent Hedgehog (Hh) inhibitor with an IC50 of 500-700 nM[1]. Jervine is a natural teratogenic sterodial alkaloid from rhizomes of Veratrum nigrum. Jervine has anti-inflammatory and antioxidant properties[2]. Jervine (11-Ketocyclopamine) is a potent Hedgehog (Hh) inhibitor with an IC50 of 500-700 nM[1]. Jervine is a natural teratogenic sterodial alkaloid from rhizomes of Veratrum nigrum. Jervine has anti-inflammatory and antioxidant properties[2].
Brachystamide D|brachystamide-D|N-isobutyl-16-(3,4-methylenedioxyphenyl)-2E,4E,15E-hexadecatrienamide|pergumidiene
C27H39NO3 (425.29297840000004)
9-(2-amino-3-(4-O-methyl-alpha-rhamnopyranosyloxy)phenyl)nonanoic acid
C22H35NO7 (425.24134000000004)
Tri-Ac-(2S,3R,4E)-2-Amino-4-octadecene-1,3-diol
C24H43NO5 (425.31410680000005)
(23R)-17,23-Epoxy-3beta-hydroxy-(13alphaH(?)-veratra-5,12(14)-dien-11-on|(23R)-17,23-epoxy-3beta-hydroxy-(13alphaH(?)-veratra-5,12(14)-dien-11-one|jervine|jervine sulfate
C27H39NO3 (425.29297840000004)
Prostaglandin D2 serinol amide
Prostaglandin E2 serinol amide
C27H39NO3_(3beta,9xi,22S,23R)-3-Hydroxy-17,23-epoxyveratraman-11-one
C27H39NO3 (425.29297840000004)
(3S,3R,3aS,6S,6aS,6bS,7aR,9R,11bR)-3-hydroxy-3,6,10,11b-tetramethylspiro[1,2,3,4,6,6a,6b,7,8,11a-decahydrobenzo[a]fluorene-9,2-3a,4,5,6,7,7a-hexahydro-3H-furo[3,2-b]pyridine]-11-one
C27H39NO3 (425.29297840000004)
1-tetradecanoyl-sn-glycero-3-phosphoethanolamine
C19H40NO7P (425.2542260000001)
Ala Ala His Lys
Ala Ala Lys His
Ala His Ala Lys
Ala His Lys Ala
Ala Lys Ala His
Ala Lys His Ala
Gly Pro Pro Arg
Gly Pro Arg Pro
Gly Arg Pro Pro
His Ala Ala Lys
His Ala Lys Ala
His Lys Ala Ala
Lys Ala Ala His
Lys Ala His Ala
Lys His Ala Ala
Asn Pro Pro Val
Asn Pro Val Pro
Asn Val Pro Pro
Pro Gly Pro Arg
Pro Gly Arg Pro
Pro Asn Pro Val
Pro Asn Val Pro
Pro Pro Gly Arg
Pro Pro Asn Val
Pro Pro Arg Gly
Pro Pro Val Asn
Pro Arg Gly Pro
Pro Arg Pro Gly
Pro Val Asn Pro
Pro Val Pro Asn
Arg Gly Pro Pro
Arg Pro Gly Pro
Arg Pro Pro Gly
Val Asn Pro Pro
Val Pro Asn Pro
Val Pro Pro Asn
PC(O-6:0/O-6:0)
C20H44NO6P (425.29060940000005)
PC(O-6:0/O-6:0)[U]
C20H44NO6P (425.29060940000005)
PC(11:0/0:0)
C19H40NO7P (425.2542260000001)
PC(11:0/0:0)[U]
C19H40NO7P (425.2542260000001)
PC(0:0/11:0)[U]
C19H40NO7P (425.2542260000001)
PC(O-12:0/0:0)[U]
C20H44NO6P (425.29060940000005)
PE(14:0/0:0)
C19H40NO7P (425.2542260000001)
PGD2-dihydroxypropanylamine
PGE2-dihydroxypropanylamine
NA 27:8;O
C27H39NO3 (425.29297840000004)
LPE 14:0
C19H40NO7P (425.2542260000001)
sodium 2-[methyloleoylamino]ethane-1-sulphonate
C21H40NNaO4S (425.2575600000001)
Piriprost
C26H35NO4 (425.25659500000006)
D004791 - Enzyme Inhibitors > D016859 - Lipoxygenase Inhibitors C471 - Enzyme Inhibitor > C1322 - Lipooxygenase Inhibitor C78568 - Prostaglandin Analogue
(3-chloro-2-hydroxypropyl)dimethyloctadecylammonium chloride
2-(((3-(Aziridin-1-yl)propanoyl)oxy)methyl)-2-ethylpropane-1,3-diyl bis(3-(aziridin-1-yl)propanoate)
C21H35N3O6 (425.25257300000004)
hexadecyl phosphate, 2-(2-hydroxyethylamino)ethanol
C20H44NO6P (425.29060940000005)
N-Boc-4-azido-L-hoMoalanine (dicyclohexylaMMoniuM) salt
Sodium N-hexadecanoyl-L-phenlyalaninate
C25H40NNaO3 (425.2905730000001)
sodium N-meethyl, N-oleoy-lamino ethyl salfonate
C21H40NaNO4S (425.2575600000001)
(1R,3S,4S)-3-[6-(5,5-DiMethyl-1,3,2-dioxaborinan-2-yl)-1H-benziMidazol-2-yl]-2-azabicyclo[2.2.1]heptane-2-carboxylic acid 1,1-diMethylethyl ester
1,3-Bis(2,6-diisopropylphenyl)-1,3,2-diazaphospholidine 2-Oxide
1-Dodecylpropanediol-3-phosphocholine
C20H44NO6P (425.29060940000005)
Diprenorphine
C26H35NO4 (425.25659500000006)
2-Azetidinecarboxylic acid, 3-(3-((aminoiminomethyl)amino)propyl)-1-((4-(((1,1-dimethylethyl)amino)carbonyl)-1-piperazinyl)carbonyl)-4-oxo-, (2S,3R)-
1-Myristoyl-2-hydroxy-sn-glycero-3-phosphoethanolamine
C19H40NO7P (425.2542260000001)
2-acyl-sn-glycero-3-phosphoethanolamine (n-C14:0)
C19H40NO7P (425.2542260000001)
1-[(4E,7E,10E,13E,16E,19E)-docosa-4,7,10,13,16,19-hexaenoyl]pyrrolidine-2-carboxylic acid
C27H39NO3 (425.29297840000004)
N-arachidonoylethanolamine phosphate(2-)
C22H36NO5P-2 (425.23309760000006)
3,9beta-Hydroxy-22alpha,23alpha-epoxy-9(10)-seco-solanida-1,3,5(10)-triene, (rel)-
C27H39NO3 (425.29297840000004)
A natural product found in Solanum campaniforme.
(9S,11R,15R,17S)-23-Methoxy-25-azatetracyclo[18.3.1.12,6.111,15]hexacosa-1(23),2,4,6(26),20(24),21-hexaene-3,9,17-triol
C26H35NO4 (425.25659500000006)
Monamphilectine A
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams
(2S)-1-[(2S)-3-methyl-2-[[(2S)-2-(methylamino)-1-oxopropyl]amino]-1-oxobutyl]-N-(5-quinolinyl)-2-pyrrolidinecarboxamide
1-dodecyl-sn-glycero-3-phosphocholine
C20H44NO6P (425.29060940000005)
1-[2-[[4,6-Bis(1-piperidinyl)-1,3,5-triazin-2-yl]oxy]ethyl]-3-phenylurea
N-[[(8R,9S)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-N-methylcarbamic acid propan-2-yl ester
C20H35N5O5 (425.26380600000005)
N-[[(8S,9S)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-N-methylcarbamic acid propan-2-yl ester
C20H35N5O5 (425.26380600000005)
N-[[(8R,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-N-methylcarbamic acid propan-2-yl ester
C20H35N5O5 (425.26380600000005)
N-[[(8R,9R)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-N-methylcarbamic acid propan-2-yl ester
C20H35N5O5 (425.26380600000005)
N-[[(8R,9S)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-N-methylcarbamic acid propan-2-yl ester
C20H35N5O5 (425.26380600000005)
N-[[(8S,9R)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-N-methylcarbamic acid propan-2-yl ester
C20H35N5O5 (425.26380600000005)
N-[[(8S,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-N-methylcarbamic acid propan-2-yl ester
C20H35N5O5 (425.26380600000005)
N-[[(8S,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N-methylcarbamic acid propan-2-yl ester
C20H35N5O5 (425.26380600000005)
1-[3-methyl-2-[[2-(methylamino)-1-oxopropyl]amino]-1-oxobutyl]-N-(5-quinolinyl)-2-pyrrolidinecarboxamide
N-[[(8S,9S)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N-methylcarbamic acid propan-2-yl ester
C20H35N5O5 (425.26380600000005)
1-[3-methyl-2-[[2-(methylamino)-1-oxopropyl]amino]-1-oxobutyl]-N-(6-quinolinyl)-2-pyrrolidinecarboxamide
N-[[(8S,9R)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N-methylcarbamic acid propan-2-yl ester
C20H35N5O5 (425.26380600000005)
2-[(3R,6aR,8S,10aR)-3-hydroxy-1-(oxan-4-ylmethyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-1-(4-methylpiperazin-1-yl)ethanone
N-[[(8R,9S)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N-methylcarbamic acid propan-2-yl ester
C20H35N5O5 (425.26380600000005)
N-[[(8R,9S)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N-methylcarbamic acid propan-2-yl ester
C20H35N5O5 (425.26380600000005)
2-[(3R,6aS,8S,10aS)-3-hydroxy-1-(oxan-4-ylmethyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-1-(4-methylpiperazin-1-yl)ethanone
N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-2-phenylacetamide
C24H31N3O4 (425.23144460000003)
N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-2-phenylacetamide
C24H31N3O4 (425.23144460000003)
N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-[[1-oxo-3-(1-piperidinyl)propyl]amino]ethyl]-3-oxanyl]-4-oxanecarboxamide
N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-[[1-oxo-3-(1-piperidinyl)propyl]amino]ethyl]-3-oxanyl]-4-oxanecarboxamide
N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-[[1-oxo-3-(1-piperidinyl)propyl]amino]ethyl]-3-oxanyl]-4-oxanecarboxamide
2-[(3R,6aR,8R,10aR)-3-hydroxy-1-(4-oxanylmethyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-1-(4-methyl-1-piperazinyl)ethanone
(8S,9S,10R)-N-cyclopentyl-10-(hydroxymethyl)-9-[4-(3-methoxyprop-1-ynyl)phenyl]-1,6-diazabicyclo[6.2.0]decane-6-carboxamide
(8R,9R,10R)-N-cyclopentyl-10-(hydroxymethyl)-9-[4-(3-methoxyprop-1-ynyl)phenyl]-1,6-diazabicyclo[6.2.0]decane-6-carboxamide
cyclohexyl-[(1R)-1-(hydroxymethyl)-7-methoxy-1-methyl-2-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]methanone
1-[(1S)-1-[cyclopropyl(oxo)methyl]-1-(hydroxymethyl)-7-methoxy-9-methyl-2-spiro[1,3-dihydropyrido[3,4-b]indole-4,3-azetidine]yl]-1-butanone
C24H31N3O4 (425.23144460000003)
(6S,7R,8R)-8-(hydroxymethyl)-4-[2-(4-morpholinyl)-1-oxoethyl]-7-(4-pent-1-ynylphenyl)-1,4-diazabicyclo[4.2.0]octan-2-one
C24H31N3O4 (425.23144460000003)
(6R,7R,8R)-8-(hydroxymethyl)-4-[2-(4-morpholinyl)-1-oxoethyl]-7-(4-pent-1-ynylphenyl)-1,4-diazabicyclo[4.2.0]octan-2-one
C24H31N3O4 (425.23144460000003)
(6S,7S,8S)-8-(hydroxymethyl)-4-[2-(4-morpholinyl)-1-oxoethyl]-7-(4-pent-1-ynylphenyl)-1,4-diazabicyclo[4.2.0]octan-2-one
C24H31N3O4 (425.23144460000003)
(6R,7S,8R)-8-(hydroxymethyl)-4-[2-(4-morpholinyl)-1-oxoethyl]-7-(4-pent-1-ynylphenyl)-1,4-diazabicyclo[4.2.0]octan-2-one
C24H31N3O4 (425.23144460000003)
N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-2-phenylacetamide
C24H31N3O4 (425.23144460000003)
N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-2-phenylacetamide
C24H31N3O4 (425.23144460000003)
N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-[[1-oxo-3-(1-piperidinyl)propyl]amino]ethyl]-3-oxanyl]-4-oxanecarboxamide
N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-[[1-oxo-3-(1-piperidinyl)propyl]amino]ethyl]-3-oxanyl]-4-oxanecarboxamide
N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-[[1-oxo-3-(1-piperidinyl)propyl]amino]ethyl]-3-oxanyl]-4-oxanecarboxamide
N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-[[1-oxo-3-(1-piperidinyl)propyl]amino]ethyl]-3-oxanyl]-4-oxanecarboxamide
N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-[[1-oxo-3-(1-piperidinyl)propyl]amino]ethyl]-3-oxanyl]-4-oxanecarboxamide
2-[(3S,6aR,8R,10aR)-3-hydroxy-1-(4-oxanylmethyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-1-(4-methyl-1-piperazinyl)ethanone
2-[(3R,6aS,8R,10aS)-3-hydroxy-1-(4-oxanylmethyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-1-(4-methyl-1-piperazinyl)ethanone
2-[(3S,6aR,8S,10aR)-3-hydroxy-1-(4-oxanylmethyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-1-(4-methyl-1-piperazinyl)ethanone
(8R,9S,10R)-N-cyclopentyl-10-(hydroxymethyl)-9-[4-(3-methoxyprop-1-ynyl)phenyl]-1,6-diazabicyclo[6.2.0]decane-6-carboxamide
(8R,9R,10S)-N-cyclopentyl-10-(hydroxymethyl)-9-[4-(3-methoxyprop-1-ynyl)phenyl]-1,6-diazabicyclo[6.2.0]decane-6-carboxamide
(8S,9S,10S)-N-cyclopentyl-10-(hydroxymethyl)-9-[4-(3-methoxyprop-1-ynyl)phenyl]-1,6-diazabicyclo[6.2.0]decane-6-carboxamide
(8S,9R,10S)-N-cyclopentyl-10-(hydroxymethyl)-9-[4-(3-methoxyprop-1-ynyl)phenyl]-1,6-diazabicyclo[6.2.0]decane-6-carboxamide
(8S,9R,10R)-N-cyclopentyl-10-(hydroxymethyl)-9-[4-(3-methoxyprop-1-ynyl)phenyl]-1,6-diazabicyclo[6.2.0]decane-6-carboxamide
(8R,9S,10S)-N-cyclopentyl-10-(hydroxymethyl)-9-[4-(3-methoxyprop-1-ynyl)phenyl]-1,6-diazabicyclo[6.2.0]decane-6-carboxamide
[(8R,9S,10S)-9-[4-[3-(dimethylamino)prop-1-ynyl]phenyl]-6-(4-oxanylmethyl)-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol
[(8S,9R,10R)-9-[4-[3-(dimethylamino)prop-1-ynyl]phenyl]-6-(4-oxanylmethyl)-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol
1-[(1R)-1-[cyclopropyl(oxo)methyl]-1-(hydroxymethyl)-7-methoxy-9-methyl-2-spiro[1,3-dihydropyrido[3,4-b]indole-4,3-azetidine]yl]-1-butanone
C24H31N3O4 (425.23144460000003)
(6S,7R,8S)-8-(hydroxymethyl)-4-[2-(4-morpholinyl)-1-oxoethyl]-7-(4-pent-1-ynylphenyl)-1,4-diazabicyclo[4.2.0]octan-2-one
C24H31N3O4 (425.23144460000003)
(6S,7S,8R)-8-(hydroxymethyl)-4-[2-(4-morpholinyl)-1-oxoethyl]-7-(4-pent-1-ynylphenyl)-1,4-diazabicyclo[4.2.0]octan-2-one
C24H31N3O4 (425.23144460000003)
(6R,7R,8S)-8-(hydroxymethyl)-4-[2-(4-morpholinyl)-1-oxoethyl]-7-(4-pent-1-ynylphenyl)-1,4-diazabicyclo[4.2.0]octan-2-one
C24H31N3O4 (425.23144460000003)
(6R,7S,8S)-8-(hydroxymethyl)-4-[2-(4-morpholinyl)-1-oxoethyl]-7-(4-pent-1-ynylphenyl)-1,4-diazabicyclo[4.2.0]octan-2-one
C24H31N3O4 (425.23144460000003)
(2R)-1-[(2S)-3-methyl-2-[[(2S)-2-(methylamino)propanoyl]amino]butanoyl]-N-quinolin-5-ylpyrrolidine-2-carboxamide
(1R,2S,6R,9S,10R,11R,14R,16S,23R,24S)-16-hydroxy-6,10,23-trimethyl-4-azahexacyclo[12.11.0.02,11.04,9.015,24.018,23]pentacos-18-ene-3,20-dione
C27H39NO3 (425.29297840000004)
1-Undecanoyl-2-hydroxy-sn-glycero-3-phosphocholine
C19H40NO7P (425.2542260000001)
2-Aminoethyl (2-hydroxy-3-pentadecoxypropyl) hydrogen phosphate
C20H44NO6P (425.29060940000005)
(3-Octoxy-2-propanoyloxypropyl) 2-(trimethylazaniumyl)ethyl phosphate
C19H40NO7P (425.2542260000001)
[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-octoxypropan-2-yl] hexanoate
C19H40NO7P (425.2542260000001)
[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-nonoxypropan-2-yl] pentanoate
C19H40NO7P (425.2542260000001)
(2-Acetyloxy-3-nonoxypropyl) 2-(trimethylazaniumyl)ethyl phosphate
C19H40NO7P (425.2542260000001)
[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-dodecoxypropan-2-yl] acetate
C19H40NO7P (425.2542260000001)
[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-decoxypropan-2-yl] butanoate
C19H40NO7P (425.2542260000001)
[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-undecoxypropan-2-yl] propanoate
C19H40NO7P (425.2542260000001)
2-[[2-(Hexanoylamino)-3-hydroxyoctoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C19H42N2O6P+ (425.27803420000004)
2-[[2-(Butanoylamino)-3-hydroxydecoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C19H42N2O6P+ (425.27803420000004)
2-[(2-Acetamido-3-hydroxydodecoxy)-hydroxyphosphoryl]oxyethyl-trimethylazanium
C19H42N2O6P+ (425.27803420000004)
2-[Hydroxy-[3-hydroxy-2-(propanoylamino)undecoxy]phosphoryl]oxyethyl-trimethylazanium
C19H42N2O6P+ (425.27803420000004)
2-[Hydroxy-[3-hydroxy-2-(pentanoylamino)nonoxy]phosphoryl]oxyethyl-trimethylazanium
C19H42N2O6P+ (425.27803420000004)
1-myristoyl-sn-glycero-3-phosphoethanolamine zwitterion
C19H40NO7P (425.2542260000001)
A 1-acyl-sn-glycero-3-phosphoethanolamine zwitterion obtained by transfer of a proton from the amino to the phosphate group of 1-myristoyl-sn-glycero-3-phosphoethanolamine; major species at pH 7.3.
Nafoxidine
D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D004965 - Estrogen Antagonists C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C1821 - Selective Estrogen Receptor Modulator C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor > C1971 - Angiogenesis Activator Inhibitor C274 - Antineoplastic Agent > C129818 - Antineoplastic Hormonal/Endocrine Agent > C481 - Antiestrogen C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C483 - Therapeutic Estrogen C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist D000970 - Antineoplastic Agents C1892 - Chemopreventive Agent
1-(4-Tert-butylcarbamoylpiperazin-1-ylcarbonyl)-3-(3-guanidinopropyl)-4-oxoazetidine-2-carboxylic acid
1-undecanoyl-sn-glycero-3-phosphocholine
C19H40NO7P (425.2542260000001)
N-(1,3-dihydroxypropan-2-yl)-9-oxo-11R,15S-dihydroxy-5Z,13E-prostadienoyl amine
PE(14:0)
C19H40NO7P (425.2542260000001)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
(3s,3'r,3'as,6's,6ar,7'ar,9s,10r,11as,11br)-3-hydroxy-3',6',10,11b-tetramethyl-1,2,3,3'a,4,4',5',6,6',6a,7,7',7'a,8,10,11a-hexadecahydro-3'h-spiro[cyclohexa[a]fluorene-9,2'-furo[3,2-b]pyridin]-11-one
C27H39NO3 (425.29297840000004)
(3z,6s)-3-({7-[(2s)-2,3-dihydroxy-3-methylbutyl]-2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl}methylidene)-6-methyl-6h-pyrazine-2,5-diol
C24H31N3O4 (425.23144460000003)
(1s,2r,3r,4r,5s,6s,8r,9s,10s,13s,16s,17r,18s)-11-ethyl-6,18-dimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,8,9,13,16-pentol
C22H35NO7 (425.24134000000004)
9-{2-amino-3-[(3,4-dihydroxy-5-methoxy-6-methyloxan-2-yl)oxy]phenyl}nonanoic acid
C22H35NO7 (425.24134000000004)
2-(10-hydroxy-3,7,9,11,13-pentamethylpentadeca-2,5,7,11,13-pentaen-1-yl)-6-methoxy-3-methylpyridin-4-ol
C27H39NO3 (425.29297840000004)
16-hydroxy-6,10,23-trimethyl-4-azahexacyclo[12.11.0.0²,¹¹.0⁴,⁹.0¹⁵,²⁴.0¹⁸,²³]pentacos-18-ene-3,20-dione
C27H39NO3 (425.29297840000004)
3-{[7-(2,3-dihydroxy-3-methylbutyl)-2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]methylidene}-5-hydroxy-6-methyl-1,6-dihydropyrazin-2-one
C24H31N3O4 (425.23144460000003)
(2s,3s)-2-[(2r,5e)-2-hydroxy-6,10-dimethylundeca-5,9-dien-2-yl]-3-methoxy-4-methyl-2h,3h-furo[3,2-c]quinolin-5-ium-5-olate
C26H35NO4 (425.25659500000006)
2-(2-hydroxy-6,10-dimethylundeca-5,9-dien-2-yl)-3-methoxy-4-methyl-2h,3h-furo[3,2-c]quinolin-5-ium-5-olate
C26H35NO4 (425.25659500000006)
11-ethyl-6,18-dimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,8,9,13,16-pentol
C22H35NO7 (425.24134000000004)
(3s,3'r,3'as,6's,6as,6br,7'ar,9r,11as,11bs)-3-hydroxy-3',6',10,11b-tetramethyl-1,2,3,3'a,4,4',5',6,6',6a,6b,7,7',7'a,8,11a-hexadecahydro-3'h-spiro[cyclohexa[a]fluorene-9,2'-furo[3,2-b]pyridin]-11-one
C27H39NO3 (425.29297840000004)
n-[(2s,3r,4r,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-2-{2-[(4e)-1,6,6-trimethyl-hexahydro-1h-inden-4-ylidene]propoxy}oxan-3-yl]ethanimidic acid
(2e,4e,15e)-16-(2h-1,3-benzodioxol-5-yl)-n-(2-methylpropyl)hexadeca-2,4,15-trienimidic acid
C27H39NO3 (425.29297840000004)
(1r,3as,3br,5as,7r,9ar,9bs,11ar)-7-hydroxy-1-[(1s)-1-(3-hydroxy-5-methylpyridin-2-yl)ethyl]-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-5-one
C27H39NO3 (425.29297840000004)
13-(hexan-2-yl)-5,8,11-trihydroxy-3,9-diisopropyl-6-methyl-1-oxa-4,7,10-triazacyclotrideca-4,7,10-trien-2-one
3-hydroxy-3',6',10,11b-tetramethyl-1,2,3,3'a,4,4',5',6,6',6a,7,7',7'a,8,10,11a-hexadecahydro-3'h-spiro[cyclohexa[a]fluorene-9,2'-furo[3,2-b]pyridin]-11-one
C27H39NO3 (425.29297840000004)
n-[4,5-dihydroxy-6-(hydroxymethyl)-2-{[1-methyl-4-(6-methylhept-5-en-2-yl)cyclohex-2-en-1-yl]oxy}oxan-3-yl]ethanimidic acid
7-hydroxy-1-[1-(3-hydroxy-5-methylpyridin-2-yl)ethyl]-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-5-one
C27H39NO3 (425.29297840000004)
(1's,2s,3s,3'r,5r,7'r)-12'-(2-hydroxyethyl)-3,3'-dimethyl-5-(2-methylprop-1-en-1-yl)-12'-azaspiro[oxolane-2,6'-tetracyclo[8.5.1.0³,⁷.0¹³,¹⁶]hexadecane]-10'(16'),13'-diene-11',15'-dione
C26H35NO4 (425.25659500000006)
(1r,3as,3bs,5as,7r,9ar,9bs,11as)-7-hydroxy-1-[(1s)-1-(3-hydroxy-5-methylpyridin-2-yl)ethyl]-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-5-one
C27H39NO3 (425.29297840000004)
2-[(2e,5e,7e,11e,13e)-10-hydroxy-3,7,9,11,13-pentamethylpentadeca-2,5,7,11,13-pentaen-1-yl]-6-methoxy-3-methylpyridin-4-ol
C27H39NO3 (425.29297840000004)
n-[4,5-dihydroxy-6-(hydroxymethyl)-2-[2-(1,6,6-trimethyl-hexahydro-1h-inden-4-ylidene)propoxy]oxan-3-yl]ethanimidic acid
(3z,6s)-3-({5-[(2s)-2,3-dihydroxy-3-methylbutyl]-2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl}methylidene)-6-methyl-6h-pyrazine-2,5-diol
C24H31N3O4 (425.23144460000003)
16-(2h-1,3-benzodioxol-5-yl)-n-(2-methylpropyl)hexadeca-2,4,15-trienimidic acid
C27H39NO3 (425.29297840000004)
(3r,6s,9s)-13-(hexan-2-yl)-5,8,11-trihydroxy-3,9-diisopropyl-6-methyl-1-oxa-4,7,10-triazacyclotrideca-4,7,10-trien-2-one
(2e)-4-[(1r,5s,7r)-1-[(2s,3e,5r,6z)-7-chloro-5,9-dihydroxynona-3,6-dien-2-yl]-6-azaspiro[4.5]decan-7-yl]-2-methylbut-2-enoic acid
C23H36ClNO4 (425.2332726000001)
3-{[5-(2,3-dihydroxy-3-methylbutyl)-2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]methylidene}-5-hydroxy-6-methyl-1,6-dihydropyrazin-2-one
C24H31N3O4 (425.23144460000003)
n-[(2r,3r,4r,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-2-{[(1s,4r)-1-methyl-4-[(2s)-6-methylhept-5-en-2-yl]cyclohex-2-en-1-yl]oxy}oxan-3-yl]ethanimidic acid
(3s,6s,8s)-3-benzyl-4,6,8,11-tetramethyl-13-(pent-4-yn-1-yl)-1-oxa-4-azacyclotridecane-2,5-dione
C27H39NO3 (425.29297840000004)
(1s,2r,3r,4s,5s,6s,8r,9s,10s,13s,16s,17r,18s)-11-ethyl-6,18-dimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,8,9,13,16-pentol
C22H35NO7 (425.24134000000004)
(3s,3'r,3'as,6's,6as,6br,7'ar,9r,11as,11br)-3-hydroxy-3',6',10,11b-tetramethyl-1,2,3,3'a,4,4',5',6,6',6a,6b,7,7',7'a,8,11a-hexadecahydro-3'h-spiro[cyclohexa[a]fluorene-9,2'-furo[3,2-b]pyridin]-11-one
C27H39NO3 (425.29297840000004)
(3z,6s)-3-({5-[(2r)-2,3-dihydroxy-3-methylbutyl]-2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl}methylidene)-6-methyl-6h-pyrazine-2,5-diol
C24H31N3O4 (425.23144460000003)